Welcome to our dedicated page for Protagonist Therapeutics SEC filings (Ticker: PTGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Protagonist Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Protagonist Therapeutics's regulatory disclosures and financial reporting.
William D. Waddill, a director of Protagonist Therapeutics, Inc. (PTGX), sold 4,000 shares of common stock on 08/27/2025 at $59.25 per share under a Rule 10b5-1 trading plan adopted on November 10, 2023. After the sale he beneficially owns 9,130 shares, held directly. The Form 4 was signed by an attorney-in-fact on 08/29/2025, and the filing indicates the transaction was effected pursuant to the pre-established 10b5-1 plan.
Protagonist Therapeutics, Inc. (PTGX) filing of Form 144 notifies a proposed sale of 4,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an approximate sale date of 08/27/2025. The shares were acquired on 05/03/2022 via previously exercised stock options and paid in cash. The filing reports an aggregate market value of $227,960.00 for the shares to be sold and indicates 62,211,318 shares outstanding for the issuer. The filer certifies they are not aware of undisclosed material adverse information and states no sales by the filer in the past three months.
State Street Corporation filed a Schedule 13G reporting beneficial ownership of common stock of Protagonist Therapeutics, Inc. The filing states State Street beneficially owns 3,207,774 shares, representing 5.2% of the outstanding class. The report shows 0 shares as sole voting power and sole dispositive power, with 3,033,685 shares of shared voting power and 3,207,774 shares of shared dispositive power.
The filing lists several State Street entities through which the position is held, including SSGA Funds Management, Inc., State Street Bank and Trust Company, and multiple State Street Global Advisors entities. The submission includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Protagonist Therapeutics (PTGX) Form 4: President & CEO Dr. Dinesh V. Patel settled 25,000 performance stock units on 07/21/25 at a cost basis of $0 after the company met pre-set corporate objectives.
To cover related tax obligations, 12,859 shares were immediately sold at a weighted-average price of $54.86. Additional discretionary sales followed: 22,065 shares on 07/22/25 at $55.05 and 17,520 shares on 07/23/25 at $54.79. In total, 52,444 shares were sold for gross proceeds of roughly $2.9 million, trimming Patel’s direct ownership from 583,462 to 531,018 shares—a reduction of about 9%.
No derivative transactions were reported. While the PSU vesting signals successful execution of 2021-vintage performance goals, the scale of secondary sales may draw investor attention to potential insider-sentiment shifts. Patel remains both a director and the largest named executive insider holder.
Protagonist Therapeutics (NASDAQ:PTGX) filed an 8-K reporting the final voting results of its 2025 Annual Meeting held on June 20, 2025.
- Directors elected: Harold E. Selick, Ph.D. (44.8 M for / 9.2 M withheld) and Bryan Giraudo (42.5 M for / 11.5 M withheld) to serve until 2028.
- Say-on-Pay: Executive compensation approved with 50.8 M votes for (92.6% of votes cast).
- Auditor ratification: Ernst & Young LLP confirmed with 55.5 M votes for (99.1%).
No other matters were brought before shareholders, and the meeting produced routine outcomes with no material corporate changes.